Strengthen cellular analysis with
cost-efficient multiomic readouts and streamlined workflows
PLEASANTON, Calif., Sept. 14,
2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq:
TXG), a leader in single cell and spatial biology, announced today
the commercial availability of a new kit to expand the capabilities
of its Chromium Single Cell Gene Expression Flex assay to include
high-throughput multiomic cellular profiling. The new kit enables
streamlined, multiomic characterization of cell populations so that
researchers can expand their options at a larger scale and detect
simultaneous gene and protein expression.
"We're building on the momentum and enthusiasm for Chromium Flex
by enabling researchers to gain more insights from a single
experiment at scale," said Ben
Hindson, Co-founder and Chief Scientific Officer at 10x
Genomics. "With this latest launch, multiomic million-cell
experiments are now accessible at a fraction of the cost."
The new Feature Barcode Multiplexing kit is part of the
company's Chromium Single Cell Gene Expression Flex portfolio,
which enables researchers to:
- Fix and store samples without losing data quality, letting
scientists run samples later and simplify transport
- Detect proteins at single cell resolution with workflows that
enable small- to large-scale studies
- Batch and scale to profile up to 1M cells in a single run and save up to 75% on
per-sample costs
- Bring scRNA-seq with industry-leading sensitivity to fresh,
frozen or fixed tissue – even FFPE
"Single cell technologies have been transformative for our
understanding of human health and disease," said Peter Skene, Director of High Resolution
Translational Immunology at the Allen Institute. "Historically,
single cell multi-omics have only profiled 1000s of cells per
experiment, limiting the depth and breadth of questions that can be
answered. New highly multiplexed single cell technologies, such as
10x Genomics Flex protein multiplex, allow the simultaneous
measurement of RNA and protein from millions of cells at a
significantly lower cost point. This is a game changer for the
research community and will expand opportunities and impact for
human health."
The new Feature Barcode Multiplexing Kit is now shipping.
About 10x Genomics
10x Genomics is a life science
technology company building products to accelerate the mastery of
biology and advance human health. Our integrated solutions include
instruments, consumables and software for single cell and spatial
biology, which help academic and translational researchers and
biopharmaceutical companies understand biological systems at a
resolution and scale that matches the complexity of biology. Our
products are behind breakthroughs in oncology, immunology,
neuroscience and more, fueling powerful discoveries that are
transforming the world's understanding of health and disease. To
learn more, visit 10xgenomics.com or connect with us on LinkedIn or
X (Twitter).
Forward Looking Statements
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 as contained in Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, which are subject
to the "safe harbor" created by those sections. All statements,
other than statements of historical facts, may be forward-looking
statements. Forward-looking statements generally can be identified
by the use of forward-looking terminology such as "may," "might,"
"will,""enable," "should," "expect," "plan," "anticipate," "could,"
"intend," "target," "project," "contemplate," "believe,"
"estimate," "predict," "potential," "would," "likely," "seek" or
"continue" or the negatives of these terms or variations of them or
similar terminology, but the absence of these words does not mean
that a statement is not forward-looking. These forward-looking
statements include statements regarding 10x Genomics, Inc.'s
expectations regarding the continued growth and expansion of our
Chromium platform, its performance and our product momentum and
progress. These statements are based on management's current
expectations, forecasts, beliefs, assumptions and information
currently available to management, and actual outcomes and results
could differ materially from these statements due to a number of
factors. The material risks and uncertainties that could affect 10x
Genomics, Inc.'s financial and operating results and cause actual
results to differ materially from those indicated by the
forward-looking statements made in this press release include those
discussed under the captions "Risk Factors" and "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" in the company's most recently-filed 10-K and elsewhere
in the documents 10x Genomics, Inc. files with the Securities and
Exchange Commission from time to time.
Although 10x Genomics, Inc. believes that the expectations
reflected in the forward-looking statements are reasonable, it
cannot provide any assurance that these expectations will prove to
be correct nor can it guarantee that the future results, levels of
activity, performance and events and circumstances reflected in the
forward-looking statements will be achieved or occur. These
forward-looking statements do not reflect the potential impact of
any future acquisitions, mergers, dispositions, joint ventures or
investments 10x Genomics, Inc. may make. Further, such
forward-looking statements may not accurately or fully reflect the
potential impact of adverse geopolitical and macroeconomic events,
product capabilities and adoption rates, international economic,
political, legal, compliance, social and business factors, such as
the COVID-19 pandemic, inflation, supply chain that may have on the
business, financial condition, results of operations and cash flows
of 10x Genomics, Inc. The forward-looking statements in this press
release are based on information available to 10x Genomics, Inc. as
of the date hereof, and 10x Genomics, Inc. disclaims any obligation
to update any forward-looking statements provided to reflect any
change in our expectations or any change in events, conditions, or
circumstances on which any such statement is based, except as
required by law. These forward-looking statements should not be
relied upon as representing 10x Genomics, Inc.'s views as of any
date subsequent to the date of this press release.
Disclosure Information
10x Genomics, Inc. uses filings
with the Securities and Exchange Commission, our website
(www.10xgenomics.com), press releases, public conference calls,
public webcasts and our social media accounts as means of
disclosing material non-public information and for complying with
our disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/10x-genomics-expands-gene-expression-flex-offering-with-new-high-throughput-multiomic-profiling-kit-301928498.html
SOURCE 10x Genomics, Inc.